Toward Explainable Anticancer Compound Sensitivity Prediction via Multimodal Attention-Based Convolutional Encoders
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
In line with recent advances in neural drug design and sensitivity prediction, we propose a novel architecture for interpretable prediction of anticancer compound sensitivity using a multimodal attention-based convolutional encoder. Our model is based on the three key pillars of drug sensitivity: compounds’ structure in the form of a SMILES sequence, gene expression profiles of tumors, and prior knowledge on intracellular interactions from protein–protein interaction networks. We demonstrate that our multiscale convolutional attention-based encoder significantly outperforms a baseline model trained on Morgan fingerprints and a selection of encoders based on SMILES, as well as the previously reported state-of-the-art for multimodal drug sensitivity prediction (R2 = 0.86 and RMSE = 0.89). Moreover, the explainability of our approach is demonstrated by a thorough analysis of the attention weights. We show that the attended genes significantly enrich apoptotic processes and that the drug attention is strongly correlated with a standard chemical structure similarity index. Finally, we report a case study of two receptor tyrosine kinase (RTK) inhibitors acting on a leukemia cell line, showcasing the ability of the model to focus on informative genes and submolecular regions of the two compounds. The demonstrated generalizability and the interpretability of our model testify to its potential for in silico prediction of anticancer compound efficacy on unseen cancer cells, positioning it as a valid solution for the development of personalized therapies as well as for the evaluation of candidate compounds in de novo drug design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adam: A Method for Stochastic Optimization
Kingma, D. P., & Ba, J. (2014) · arXiv · doi:10.48550/arxiv.1412.6980 · Cited by 98,946
Enrichr: a comprehensive gene set enrichment analysis web server 2016 update
Kuleshov, M. V., Jones, M. R., Rouillard, A. D., Fernandez, N. F., Duan, Q., Wang, Z., Koplev, S., Jenkins, S. L., Jagodnik, K. M., Lachmann, A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw377 · Cited by 10,799
STRING v10: protein–protein interaction networks, integrated over the tree of life
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1003 · Cited by 10,436 · cited 1×
“Each of the 985 cell lines was initially represented by the expression levels of 17,737 genes which we then reduced to a subset of 2128 genes through network propagation over the STRING protein-protein interaction (PPI) network (Szklarczyk et al., 2014), a comprehensive PPI database including interactions from multipl…”
MethodEnrichr: interactive and collaborative HTML5 gene list enrichment analysis tool
Chen, E. Y., Tan, C. M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G. V., Clark, N. R., & Ma’ayan, A. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-128 · Cited by 7,814 · cited 1×
“Based on the resulting subset of 371 highly attended genes, we performed a pathway enrichment analysis using Enrichr (Chen et al., 2013; Kuleshov et al., 2016).”
MethodWeininger, D. (1988) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci00057a005 · Cited by 7,436
Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1111 · Cited by 4,051
MoleculeNet: a benchmark for molecular machine learning
Wu, Z., Ramsundar, B., Feinberg, E. N., Gomes, J., Geniesse, C., Pappu, A. S., Leswing, K., & Pande, V. (2018) · Chemical Science · doi:10.1039/c7sc02664a · Cited by 3,107
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 1×
“There have been a plethora of works on the prediction of drug sensitivity in cancer cells (Garnett et al., 2012; Yang et al., 2012; Costello et al., 2014; Ali & Aittokallio, 2018; Kalamara et al., 2018).”
The rise of deep learning in drug discovery
Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.039 · Cited by 1,770
Generating Focused Molecule Libraries for Drug Discovery with Recurrent Neural Networks
Segler, M. H. S., Kogej, T., Tyrchan, C., & Waller, M. P. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00512 · Cited by 1,537
Cited by
Drug discovery with explainable artificial intelligence
Jiménez-Luna, J., Grisoni, F., & Schneider, G. (2020) · Nature Machine Intelligence · doi:10.1038/s42256-020-00236-4 · Cited by 1,063
Explainable artificial intelligence: a comprehensive review
Minh, D., Wang, H. X., Li, Y. F., & Nguyen, T. N. (2022) · Artificial Intelligence Review · doi:10.1007/s10462-021-10088-y · Cited by 983
Pyzer-Knapp, E. O., Pitera, J. W., Staar, P. W. J., Takeda, S., Laino, T., Sanders, D. P., Sexton, J., Smith, J. R., & Curioni, A. (2022) · npj Computational Materials · doi:10.1038/s41524-022-00765-z · Cited by 465
“Another approach is a combination of VAE and reinforcement learning (RL) 61,62 , where drug molecules ’ SMILES and target proteins are both encoded on a common latent space.”
BackgroundMethodArtificial intelligence for natural product drug discovery
Mullowney, M. W., Duncan, K. R., Elsayed, S. S., Garg, N., van der Hooft, J. J. J., Martin, N. I., Meijer, D., Terlouw, B. R., Biermann, F., Blin, K., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00774-7 · Cited by 460
Attention is all you need: utilizing attention in AI-enabled drug discovery
Zhang, Y., Liu, C., Liu, M., Liu, T., Lin, H., Huang, C.-B., & Ning, L. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad467 · Cited by 377
Deep generative molecular design reshapes drug discovery
Zeng, X., Wang, F., Luo, Y., Kang, S.-G., Tang, J., Lightstone, F. C., Fang, E. F., Cornell, W., Nussinov, R., & Cheng, F. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100794 · Cited by 295
ŞAHiN, E., Arslan, N. N., & Özdemir, D. (2025) · Neural Computing and Applications · doi:10.1007/s00521-024-10437-2 · Cited by 278
DeepCDR: a hybrid graph convolutional network for predicting cancer drug response
Liu, Q., Hu, Z., Jiang, R., & Zhou, M. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa822 · Cited by 263
A Review on Explainability in Multimodal Deep Neural Nets
Joshi, G., Walambe, R., & Kotecha, K. (2021) · IEEE Access · doi:10.1109/access.2021.3070212 · Cited by 204
“[4],[184],[178], [210],[177], [181],[79],[176] ,[188],[211], [212],[19],[123] ,[213],[214], [215] Attentionbased approach Explanations based on attention to capture the important visual and textual regions that contribute to a prediction.”
BackgroundEnhancing scientific discoveries in molecular biology with deep generative models
Lopez, R., Gayoso, A., & Yosef, N. (2020) · Molecular Systems Biology · doi:10.15252/msb.20199198 · Cited by 82
“However, accurately recovering treatment effect from observational (rather than interventional) data requires first that there are no hidden confounders that control treatment outcome and second that it was feasible to assign to each observed case actions different from the one observed.”
BackgroundThe EFFECT benchmark suite: measuring cancer sensitivity prediction performance - without the bias
Szalai, B., Gáspár, I., Kaszás, V., Mérő, L., Sztilkovics, M., & Szalay, K. Z. (2023) · doi:10.1101/2023.10.02.560281 · Cited by 5
Learning chemical sensitivity reveals mechanisms of cellular response
Connell, W., Garcia, K., Goodarzi, H., & Keiser, M. J. (2024) · Communications Biology · doi:10.1038/s42003-024-06865-4 · Cited by 4
Metadata
- Authors
- Manica, M., Oskooei, A., Born, J., Subramanian, V., Sáez-Rodríguez, J., & Rodríguez Martínez, M.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-10-16
- Volume
- 16
- Issue
- 12
- Pages
- 4797-4806
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2942173509
- Cited by
- 147
- References
- 11
- FWCI
- 12.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.